論文

2021年

Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR)

Journal of Clinical and Experimental Hematopathology
  • Koji Izutsu
  • ,
  • Junji Suzumiya
  • ,
  • Jun Takizawa
  • ,
  • Kenjiro Fukase
  • ,
  • Maki Nakamura
  • ,
  • Masahisa Jinushi
  • ,
  • Hirokazu Nagai

61
3
開始ページ
135
終了ページ
144
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3960/jslrt.20056
出版者・発行元
Japanese Society for Lymphoreticular Tissue Research

Mantle cell lymphoma (MCL) accounts for approximately 3% of all cases of malignant lymphoma in Japan. The CLIMBER-DBR (Treatment practices and patient burden in chronic lymphocytic leukemia and mantle cell lymphoma patients in the real world: An observational database research in Japan) study examined the clinical characteristics, treatment patterns, and health-care resource utilization of MCL in a real-world clinical setting in Japan. Using the Japanese Medical Data Vision database, we extracted data for 1130 patients with MCL (ICD-10 code C83.1) registered between March 1, 2013 and February 28, 2018. The date of first MCL diagnosis was taken as the index date. The mean (standard deviation) age, body weight, and modified Charlson Comorbidity Index were 71.4 (10.9) years, 58.3 (11.7) kg, and 1.9 (1.6). respectively, and 24.6% were <= 65 years old. The median follow-up period was 654 days (first-third quartile 290.5-1049 days). A total of 802 patients (71.0%) underwent first-line treatment. The most common first-line treatment was bendamustine/rituximab (BR; 27.8%), followed by rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-CHOP; 15.6%) and rituximab/tetrahydropyranyl-adriamycin/cyclo-phosphamide/vincristine/prednisolone (R-THP-COP; 6.5%). The median (95% confidence interval) times to initial (first-line), second-line, and third-line treatments were 45 (36-62), 687 (624-734), and 1188 (1099-1444) days, respectively. Treatment practices for MCL in Japan are consistent with trends observed in Western countries. Our study can serve as a benchmark to assess future MCL treatments in Japan.

リンク情報
DOI
https://doi.org/10.3960/jslrt.20056
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000696804600003&DestApp=WOS_CPL
URL
https://www.jstage.jst.go.jp/article/jslrt/61/3/61_20056/_pdf
ID情報
  • DOI : 10.3960/jslrt.20056
  • ISSN : 1346-4280
  • eISSN : 1880-9952
  • Web of Science ID : WOS:000696804600003

エクスポート
BibTeX RIS